ConductScience.org, home

Paper41004573

Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH.

Yu X and 23 others. Sci Adv, 2025. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH. Papers, record 41004573. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41004573

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH.
PubMed
Journal
Sci Adv
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
4.53, provisional
iCite
Revised in PubMed
2026-08-27
PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CeramidesMajor topic
LiverMajor topic
Fatty LiverMajor topic
Animals
Humans
Mice
Hepatocytes
Disease Models, Animal
Lipogenesis
Male
RNA, Small Interfering
Serine C-Palmitoyltransferase
Diet, High-Fat
Mice, Inbred C57BL
Nanoparticles

Source PubMed

Download CSV of topics

References76

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138300524Ceramides are fuel gauges on the drive to cardiometabolic disease.Physiol Rev2024https://conductscience.org/library/papers/38300524PubMed
234139255Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.Adv Drug Deliv Rev2021https://conductscience.org/library/papers/34139255PubMed
325295789CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance.Cell Metab2014https://conductscience.org/library/papers/25295789PubMed
431728041Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism.Sci Rep2019https://conductscience.org/library/papers/31728041PubMed
528038954Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA.Nanomedicine2017https://conductscience.org/library/papers/28038954PubMed
631805015Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.J Clin Invest2020https://conductscience.org/library/papers/31805015PubMed
725500885Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.J Clin Invest2015https://conductscience.org/library/papers/25500885PubMed
840015281Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism.Cell Metab2025https://conductscience.org/library/papers/40015281PubMed
922707395Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.Hepatology2012https://conductscience.org/library/papers/22707395PubMed
1024827819Effect of methionine-deficient and methionine-supplemented diets on the hepatic one-carbon and lipid metabolism in mice.Mol Nutr Food Res2014https://conductscience.org/library/papers/24827819PubMed
1121286345Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.Hepatol Int2010https://conductscience.org/library/papers/21286345PubMed
1236753562Hepatocytes demarcated by EphB2 contribute to the progression of nonalcoholic steatohepatitis.Sci Transl Med2023https://conductscience.org/library/papers/36753562PubMed
1333045403The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.Contemp Clin Trials2020https://conductscience.org/library/papers/33045403PubMed
1427125947Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.Eur Heart J2016https://conductscience.org/library/papers/27125947PubMed
1525061561Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels.Mol Metab2014https://conductscience.org/library/papers/25061561PubMed
1620395294Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione.J Biol Chem2010https://conductscience.org/library/papers/20395294PubMed
1719731235Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.Hepatology2009https://conductscience.org/library/papers/19731235PubMed
1829155055Cell culture models of fatty acid overload: Problems and solutions.Biochim Biophys Acta Mol Cell Biol Lipids2018https://conductscience.org/library/papers/29155055PubMed
1933991378Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort.J Magn Reson Imaging2021https://conductscience.org/library/papers/33991378PubMed
2016960033Ceramide synthase inhibition by fumonisin B1 treatment activates sphingolipid-metabolizing systems in mouse liver.Toxicol Sci2006https://conductscience.org/library/papers/16960033PubMed

See all 76 referencesDownload CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
42989274Beyond cholesterol: targeting ceramide signaling in cardiorenal metabolic crosstalk.Cardiovasc Diabetol2026https://conductscience.org/library/papers/42989274PubMed
42941815Sphingolipid Dysregulation in Type 2 Diabetes and Its Microvascular Complications.Int J Mol Sci2026https://conductscience.org/library/papers/42941815PubMed
42883860Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes.Int J Mol Sci2026https://conductscience.org/library/papers/42883860PubMed
42866058Omics-based Decoding of Metabolic Dysfunction-associated Fatty Liver Disease: From Pathogenesis to Clinical Translation.J Clin Transl Hepatol2026https://conductscience.org/library/papers/42866058PubMed
42703427Nanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems.Int J Nanomedicine2026https://conductscience.org/library/papers/42703427PubMed
42542256A targeted lipidomics workflow for high-throughput phenotyping and mechanism-based in vitro hepatotoxicity studies.Toxicol In Vitro2026https://conductscience.org/library/papers/42542256PubMed
42540234Bixin and Montelukast Combination Mitigates the Progression of MASLD to Cytokine-Driven Inflammatory Stress in an In Vitro Fluid-Dynamic Model.ACS Omega2026https://conductscience.org/library/papers/42540234PubMed
42461367Lipidomics and proteomics in MASLD: reading the molecular script toward precision therapeutics.Hormones (Athens)2026https://conductscience.org/library/papers/42461367PubMed
42346401Ceramide-Driven Mechanisms in Pulmonary Fibrosis.Metabolites2026https://conductscience.org/library/papers/42346401PubMed
42239544Sphingolipid homeostasis and dysregulation in liver function and disease.Life Metab2026https://conductscience.org/library/papers/42239544PubMed
42116125Gene therapy for liver diseases: methods, challenges and opportunities.J Nanobiotechnology2026https://conductscience.org/library/papers/42116125PubMed
42111262Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease.Front Cell Dev Biol2026https://conductscience.org/library/papers/42111262PubMed
42021356Untargeted plasma lipidomic profiling associated with pediatric metabolic dysfunction-associated steatohepatitis (MASH).Lipids Health Dis2026https://conductscience.org/library/papers/42021356PubMed
41706239MASLD biomarker discovery: evaluating lipidomics techniques across disease progression.Mol Biol Rep2026https://conductscience.org/library/papers/41706239PubMed
41527118Targeted analysis of sphingolipids and cytokines in plasma of dairy cows after calving reveals distinct impacts of systemic inflammation, ketosis, and mastitis.J Anim Sci Biotechnol2026https://conductscience.org/library/papers/41527118PubMed
41194880Anti-obesity effects of Wumeishanzhayin: an integrated lipidomics and transcriptomics study.Front Pharmacol2025https://conductscience.org/library/papers/41194880PubMed

Download CSV of cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41004573

GET https://conductscience.org/api/papers/v1/41004573/authors?page=2